CAR T Cell Therapy | CHOP Research Institute

CAR T Cell Therapy

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 ("study drug").

Published on
Sep 19, 2022
CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

weberew [at]
Published on
Dec 10, 2021
Our research news highlights a study about sequencing bone marrow DNA after CAR T-cell therapy and how it accurately predicts leukemia relapse.
Published on
Jul 8, 2021
The “Pediatric Cancer Dream Team”, co-led by Dr. John Maris, received the Team Science Award from the AACR.

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19.

The purpose of this study is to test if the CD19 CAR T cell product tisagenlecleucel  is safe and has beneficial effects in children and young adults who have newly diagnosed high-risk B-cell Acute Lymphoblastic Leukemia that remains MRD-positive after 2 cycles of chemotherapy.

This purpose of this study is to determine the efficacy and safety of tisagenlecleucel (also referred to as CTL019, or Kymriah™) in children, adolescents and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

Published on
Oct 7, 2020
Researchers used T Cells from the lymphatic fluid instead of blood for CAR T-Cell therapy.
Published on
Oct 21, 2019
Stephan Grupp, MD, PhD, Chief of the Cell Therapy and Transplant Section in the Division of Oncology, has been elected into the National Academy of Medicine (NAM).